INTRODUCTION.
Human ovarian adenocarcinoma N.1 cells apoptose upon Myc-activation when serum factors are limited (1) . The downstream mechanism that is triggered by Myc is unknown, however. We discovered that Myc-activation and treatment with TNFa, FasL and TRAIL induces H-ferritin expression. H-ferritin is an intracellular iron chelator. Since also the pharmacological iron chelator deferoxamine induces apoptosis in N.1 cells, we investigated the regulation and the role of H-ferritin in response to Myc-activation and TNFa treatment under serum free, pro-apoptotic conditions, and identified transferrin as a survival factor in N.1 human ovarian carcinoma cells.
METHODS.
Western blotting, northern blotting and DNA fragmentation and apoptosis assays were performed according to standard procedures and transfection and retroviral transduction according to standard protocols.
RESULTS. When N.1 cells are treated with TRAIL, FasL or TNFa under serum deprived cell culture conditions, which is a prerequisite to induce apoptosis, H-ferritin becomes upregulated (Fig. 1a) . Under non-apoptotic conditions, i.e. when cells are maintained under 10% fetal calf serum, the treatment with these inducers prevents cell death (2) and also H-ferritin levels are not induced (Fig. 1b) . Activation of an ectopic Myc:ER construct also induces H-ferritin expression when serum is withdrawn, not however in presence of serum. Therefore we assumed that intracellular iron sequestration might be a trigger mechanism of Myc-induced apoptosis. Hence, transferrin was substituted for serum and this, in fact, rescues from apoptosis and does not allow for H-ferritin induction (Fig. 1c) . Substitution of transferrin for serum also aborts cell death elicited by TNFa, FasL and TRAIL (Fig. 2) , and moreover, prevents downregulation of Akt during TNFa-treatment.
